ArticleInternational dental journal2026
Mitochondrial Metabolic Biomarkers in Periodontitis: Discovery and Clinical Validation.
Article in International dental journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
INTRODUCTION AND
aimsMitochondrial metabolic dysregulation is associated with periodontitis (PD); however, related biomarkers remain unclear. In this study, we identified key mitochondrial metabolism-related biomarkers in PD through integrated bioinformatics technology.
methodsTranscriptomic and single-cell RNA sequencing data from the Gene Expression Omnibus database were analysed using machine learning to identify biomarkers. A diagnostic nomogram was constructed. Immune infiltration, drug prediction, and T-cell dynamic expression were assessed. Putative biomarkers were validated in clinical samples and a rat PD model by reverse transcription-quantitative polymerase chain reaction, immunohistochemistry, and Western blot analysis.
resultsSix biomarkers were identified, which included ENTPD1, CYP24A1, ADA, TDO2 (upregulated), OSBPL6, and NUDT15 (downregulated). The nomogram exhibited excellent diagnostic efficacy (area under the curve [AUC] = 0.954). The biomarkers correlated with plasma cells and resting dendritic cells. Single-cell analysis revealed dynamic expression during T-cell differentiation. CTA018 exhibited strong binding to CYP24A1. Five biomarkers were validated in clinical samples, and the upregulation of ENTPD1, CYP24A1, and TDO2 protein and messenger RNA was confirmed in a rat model and correlated with PD progression.
conclusionENTPD1, CYP24A1, and TDO2 are mitochondrial metabolism-related biomarkers with high diagnostic potential in PD and targets for therapy. CLINICAL RELEVANCE: The identified biomarkers, particularly ENTPD1, CYP24A1, and TDO2, have strong diagnostic value. The nomogram contributed to PD risk stratification. Associations with immune infiltration and drug sensitivity may guide immunotherapy and targeted therapy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.